WASHINGTON — In a major expansion of the pandemic treatment toolkit, the U.S. Food and Drug Administration (FDA) has officially approved Shionogi’s Xocova (ensitrelvir). The milestone marks the authorization of the first oral antiviral specifically designed for post-exposure prophylaxis (prevention) of COVID-19.
The medication is approved for adults and adolescents aged 12 and older who have had direct contact with an infected individual, offering a vital line of defense for household members and close contacts aiming to block the virus before symptoms take hold.
Unlike treatments like Paxlovid, which are administered after a person tests positive and starts showing symptoms, Xocova’s post-exposure protocol focuses entirely on halting early viral replication.
In rigorous clinical trials, investigators found that starting the medication shortly after close contact with a confirmed COVID-19 case reduced the risk of developing symptomatic infection by 67% compared to a placebo.
Dosage and What to Expect
The medication is designed as a short, straightforward course to swiftly suppress the virus:
- The Regimen: A 5-day oral treatment.
- The Schedule: Patients take a “loading dose” of three tablets on Day 1, followed by a single maintenance tablet daily on Days 2 through 5.
- Side Effects: The drug was generally well-tolerated in clinical settings. The most common side effects reported by trial participants included headache, diarrhea, and a mild cough.
While vaccines remain the primary defense against severe disease, and existing antivirals help those who are already sick, public health experts have long pointed out a missing link: protecting vulnerable people immediately after they’ve been exposed.
Xocova works as a protease inhibitor, specifically targeting the 3CL protease—an enzyme the coronavirus fundamentally requires to replicate itself inside human cells. By choking off this replication process early, the drug gives the immune system a decisive upper hand.
Originally developed through a partnership between Shionogi and Hokkaido University, the drug previously received emergency regulatory approval in Japan, where it has been widely utilized. This FDA approval broadens its reach significantly, establishing a proactive strategy to stop household transmission chains before they disrupt families and workplaces.
Medical providers note that Xocova will be especially valuable for high-risk individuals, immunocompromised patients, or multi-generational households where isolating from an infected family member is logistically impossible.
